Company Filing History:
1 out of 3 
1 out of 2 Years Active: 2000
Title: David Cooper - Innovator in HIV Research
Introduction
David Cooper is a prominent inventor based in Bellevue Hill, Australia. He is known for his significant contributions to the field of medical research, particularly in the study of human immunodeficiency virus type 1 (HIV-1). His innovative work has led to advancements in understanding non-pathogenic strains of HIV-1.
Latest Patents
David Cooper holds a patent for non-pathogenic strains of HIV-1 containing mutations in the NEF gene. This invention focuses on HIV-1 strains that have deletions in the nef gene and U3 region of the long terminal repeat (LTR). His research has identified long-term nonprogressors (LTNPs) who remain free of HIV-1-related disease, highlighting the importance of specific genetic deletions in determining the pathogenicity of HIV-1.
Career Highlights
Throughout his career, David Cooper has worked with esteemed organizations such as the Macfarlane Burnet Centre for Medical Research Limited and the Australian Red Cross Society. His dedication to medical research has made a lasting impact on the understanding and treatment of HIV.
Collaborations
David has collaborated with notable colleagues, including Nicholas John Deacon and Jennifer Catherine Learmont. These partnerships have contributed to the advancement of research in the field of HIV and have fostered a collaborative environment for innovation.
Conclusion
David Cooper